Loading...
•
Sep 30, 2023
Cocrystal Pharma Q3 2023 Earnings Report
Cocrystal Pharma's financial results for Q3 2023 were reported, along with updates on antiviral drug development programs.
Key Takeaways
Cocrystal Pharma reported a net loss of $4.2 million, or $0.41 per share, for the third quarter of 2023, compared to a net loss of $5.7 million, or $0.70 per share, for the third quarter of 2022. The company's cash position is believed to be sufficient to fund planned operations beyond the next 12 months.
Phase 2a human challenge study for CC-42344 expected to begin before year-end.
Phase 1 healthy volunteer trial for inhaled CC-42344 anticipated in the first half of 2024.
Enrollment is underway in a Phase 1 trial with CDI-988.
Current cash position is sufficient to fund planned operations beyond the next 12 months.
Forward Guidance
Cocrystal Pharma believes its current cash position is sufficient to fund planned operations beyond the next 12 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...